A systematic review and meta-analysis on sodium tanshinone IIA sulfonate injection for the adjunctive therapy of pulmonary heart disease.

Huikai Shao, Fei Yu, Dongsheng Xu, Chunyan Fang, Rongsheng Tong, Lingguo Zhao
Author Information
  1. Huikai Shao: Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
  2. Fei Yu: Sinopharm Dongfeng General Hospital, Hubei University of Medicine, 442008, Shiyan, China.
  3. Dongsheng Xu: Institute of Pharmaceutical Analysis, College of Pharmacy, Jinan University, Guangzhou, 510006, China.
  4. Chunyan Fang: TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China. 1039453631@qq.com.
  5. Rongsheng Tong: Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China. tongrs@126.com.
  6. Lingguo Zhao: Center for Disease Prevention and Control of Baoan District, Shenzhen, 518101, China. zhaolingguo2008@163.com.

Abstract

AIMS: Sodium tanshinone IIA sulfonate (STS) injection has been widely used as adjunctive therapy for pulmonary heart disease (PHD) in China. Nevertheless, the efficacy of STS injection has not been systematically evaluated so far. Hence, the efficacy of STS injection as adjunctive therapy for PHD was explored in this study.
METHODS: Randomized controlled trials (RCTs) were screened from China Science and Technology Journal Database, China National Knowledge Infrastructure, Wanfang Database, PubMed, Sino-Med, Google Scholar, Medline, Chinese Biomedical Literature Database, Cochrane Library, Embase and Chinese Science Citation Database until 20 January 2024. Literature searching, data collection and quality assessment were independently performed by two investigators. The extracted data was analyzed with RevMan 5.4 and STATA 14.0. Basing on the methodological quality, dosage of STS injection, control group measures and intervention time, sensitivity analysis and subgroup analysis were performed.
RESULTS: 19 RCTs with 1739 patients were included in this study. Results showed that as adjunctive therapy, STS injection combined with Western medicine showed better therapeutic efficacy than Western medicine alone for PHD by increasing the clinical effective rate (RR = 1.22; 95% CI, 1.17 to 1.27; p < 0.001), partial pressure of oxygen (MD = 10.16; 95% CI, 5.07 to 15.24; p < 0.001), left ventricular ejection fraction (MD = 8.66; 95% CI, 6.14 to 11.18; p < 0.001) and stroke volume (MD = 13.10; 95% CI, 11.83 to 14.38; p < 0.001), meanwhile decreasing the low shear blood viscosity (MD = -1.16; 95% CI, -1.57 to -0.74; p < 0.001), high shear blood viscosity (MD = -0.64; 95% CI, -0.86 to -0.42; p < 0.001), plasma viscosity (MD = -0.23; 95% CI, -0.30 to -0.17; p < 0.001), hematokrit (MD = -8.52; 95% CI, -11.06 to -5.98; p < 0.001), fibrinogen (MD = -0.62; 95% CI, -0.87 to -0.37; p < 0.001) and partial pressure of carbon dioxide (MD = -8.56; 95% CI, -12.09 to -5.02; p < 0.001).
CONCLUSION: STS injection as adjunctive therapy seemed to be more effective than Western medicine alone for PHD. However, due to low quality of the included RCTs, more well-designed RCTs were necessary to verify the efficacy of STS injection.

Keywords

References

  1. Medicine (Baltimore). 2021 Jan 8;100(1):e24131 [PMID: 33429786]
  2. BMC Complement Altern Med. 2015 Nov 24;15:418 [PMID: 26603978]
  3. PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
  4. Front Pharmacol. 2020 May 07;11:634 [PMID: 32457624]
  5. Control Clin Trials. 1996 Feb;17(1):1-12 [PMID: 8721797]
  6. Front Pharmacol. 2021 Nov 22;12:761722 [PMID: 34880757]
  7. BMC Complement Med Ther. 2023 Feb 6;23(1):38 [PMID: 36747221]
  8. PLoS One. 2017 May 22;12(5):e0178226 [PMID: 28542554]
  9. Phytomedicine. 2022 Jan;95:153879 [PMID: 34906894]
  10. BMC Complement Altern Med. 2018 Jan 31;18(1):41 [PMID: 29386000]
  11. Complement Ther Med. 2021 Jun;59:102691 [PMID: 33618010]
  12. Pulm Circ. 2013 Jan;3(1):5-19 [PMID: 23662171]
  13. Biomed Pharmacother. 2019 Oct;118:109362 [PMID: 31545252]
  14. J Altern Complement Med. 2011 Jul;17(7):579-87 [PMID: 21711201]
  15. BMC Complement Med Ther. 2020 Apr 15;20(1):112 [PMID: 32293408]
  16. Front Cardiovasc Med. 2022 Feb 24;9:763567 [PMID: 35282378]
  17. Med Sci Monit. 2015 Nov 29;21:3704-15 [PMID: 26615387]
  18. Am J Chin Med. 2014;42(6):1315-31 [PMID: 25395310]
  19. Semin Respir Crit Care Med. 2003 Jun;24(3):233-44 [PMID: 16088545]
  20. Evid Based Complement Alternat Med. 2012;2012:716459 [PMID: 22454677]
  21. Am J Respir Cell Mol Biol. 2013 Jan;48(1):125-34 [PMID: 23065131]
  22. Am J Physiol Cell Physiol. 2016 Jul 1;311(1):C136-49 [PMID: 27194472]
  23. Biosci Rep. 2020 Mar 27;40(3): [PMID: 32124923]
  24. Evid Based Complement Alternat Med. 2012;2012:792726 [PMID: 21860655]
  25. J Ethnopharmacol. 2009 Sep 25;125(3):436-43 [PMID: 19635545]
  26. Heart Lung Circ. 2018 Apr;27(4):433-442 [PMID: 29150156]
  27. Front Pharmacol. 2018 May 01;9:263 [PMID: 29765317]
  28. Medicine (Baltimore). 2018 Sep;97(39):e12461 [PMID: 30278529]

Grants

  1. 2021M690559/China Postdoctoral Science Foundation
  2. 2022NSFSC1327/Natural Science Foundation of Sichuan Province
  3. 21Y78/Scientific and Technological Project of Shiyan City of Hubei Province
  4. 2020A1515110867/Basic and Applied Basic Research Foundation of Guangdong Province
  5. A2021416/Guangdong Medical Research Foundation

MeSH Term

Humans
Pulmonary Heart Disease
Injections
Phenanthrenes
Drugs, Chinese Herbal

Chemicals

tanshinone II A sodium sulfonate
Phenanthrenes
Drugs, Chinese Herbal

Word Cloud

Created with Highcharts 10.0.095%CIp < 0001-0injectionSTStherapyMD=adjunctivePHDefficacyRCTsDatabasetanshinoneIIAsulfonateheartdiseaseChinaquality14WesternmedicineviscositySodiumpulmonarystudyScienceChineseLiteraturedataperformed5analysisincludedshowedaloneeffective117partialpressure1611lowshearblood-1-8-5reviewAIMS:widelyusedNeverthelesssystematicallyevaluatedfarHenceexploredMETHODS:RandomizedcontrolledtrialsscreenedTechnologyJournalNationalKnowledgeInfrastructureWanfangPubMedSino-MedGoogleScholarMedlineBiomedicalCochraneLibraryEmbaseCitation20January2024searchingcollectionassessmentindependentlytwoinvestigatorsextractedanalyzedRevMan4STATA0BasingmethodologicaldosagecontrolgroupmeasuresinterventiontimesensitivitysubgroupRESULTS:191739patientsResultscombinedbettertherapeuticincreasingclinicalrateRR = 12227oxygenMD = 10071524leftventricularejectionfractionMD = 866618strokevolumeMD = 13108338meanwhiledecreasing5774high648642plasma2330hematokrit52-110698fibrinogen628737carbondioxide56-120902CONCLUSION:seemedHoweverduewell-designednecessaryverifysystematicmeta-analysissodiumAdjunctiveMeta-analysisPulmonarySystematic

Similar Articles

Cited By